Please login (Members) to view content or
(Nonmembers) this article.
Average: 5 (1 vote)
Oncology Update

Oncology Update

Michael Smart
ONF 2011, 38(6), 739-740 DOI: 10.1188/11.ONF.739-740

Crizotinib (Xalkori®), an oral anaplastic lymphoma kinase (ALK) inhibitor, has received U.S. Food and Drug Administration (FDA) approval for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has tested positive for ALK gene abnormalities.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or